{"id":60547,"date":"2026-03-23T15:00:03","date_gmt":"2026-03-23T07:00:03","guid":{"rendered":"https:\/\/flcube.com\/?p=60547"},"modified":"2026-03-23T15:00:03","modified_gmt":"2026-03-23T07:00:03","slug":"dizal-reports-positive-wu-kong28-results-zegfrovy-first-line-win-positions-as-first-chemo-free-egfr-exon20ins-nsclc-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60547","title":{"rendered":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy"},"content":{"rendered":"\n<p><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 68819<\/a>2) announced that its <strong>multinational Phase 3 WU\u2011KONG28 study<\/strong> evaluating <strong>ZEGFROVY (sunvozertinib)<\/strong> as <strong>first\u2011line monotherapy<\/strong> in <strong>non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins)<\/strong> met its <strong>primary endpoint<\/strong>, demonstrating <strong>significant PFS improvement<\/strong> vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the <strong>potential first and only chemo\u2011free, oral first\u2011line agent<\/strong> for this underserved mutation subtype.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone-wu-kong28-phase-3\">Clinical Milestone \u2013 WU\u2011KONG28 Phase 3<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>WU\u2011KONG28 (multinational, open\u2011label, randomized, confirmatory Phase 3)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ZEGFROVY (sunvozertinib) \u2013 irreversible EGFR inhibitor<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Dizal Pharmaceutical Co., Ltd. (SHA: 688192)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line treatment of advanced NSCLC with EGFR exon20ins<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Platinum\u2011based doublet chemotherapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression\u2011free survival (PFS) \u2013 BICR\u2011assessed<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td><strong>Significant PFS improvement<\/strong> vs. chemotherapy; <strong>meaningful clinical benefit<\/strong> demonstrated<\/td><\/tr><tr><td><strong>Strategic Positioning<\/strong><\/td><td>Potential <strong>first chemo\u2011free, oral first\u2011line agent<\/strong> for EGFR exon20ins NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>ZEGFROVY (sunvozertinib)<\/strong> \u2013 <strong>irreversible EGFR inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Discovery:<\/strong> <strong>Dizal scientists<\/strong> (independently developed)<\/li>\n\n\n\n<li><strong>Target Spectrum:<\/strong> Wide range of <strong>EGFR mutations<\/strong> with <strong>wild\u2011type EGFR selectivity<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong><\/li>\n\n\n\n<li><strong>Oral administration<\/strong> vs. IV chemotherapy<\/li>\n\n\n\n<li><strong>Chemo\u2011free regimen<\/strong> \u2013 reduced systemic toxicity<\/li>\n\n\n\n<li><strong>First\u2011line positioning<\/strong> \u2013 addresses unmet need in newly diagnosed exon20ins patients<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status-amp-commercial-footprint\">Regulatory Status &amp; Commercial Footprint<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Status<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td><strong>Approved<\/strong><\/td><td>Post\u2011platinum EGFR exon20ins NSCLC (locally advanced\/metastatic)<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td><strong>Approved<\/strong><\/td><td>Post\u2011platinum EGFR exon20ins NSCLC<\/td><\/tr><tr><td><strong>First\u2011Line Expansion<\/strong><\/td><td>WU\u2011KONG28 positive results<\/td><td>sNDA submission anticipated H2 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-implications\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>EGFR exon20ins NSCLC Landscape<\/th><th>ZEGFROVY Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Prevalence<\/strong><\/td><td>~10\u201112% of EGFR\u2011mutant NSCLC; ~30,000 new cases annually (US+EU+China)<\/td><td>First\u2011line approval would expand addressable market 3\u20114x vs. current post\u2011chemo indication<\/td><\/tr><tr><td><strong>Standard of Care (1L)<\/strong><\/td><td>Platinum\u2011based chemotherapy (pemetrexed + carboplatin\/cisplatin) \u2013 limited efficacy, high toxicity<\/td><td><strong>Chemo\u2011free oral alternative<\/strong> with superior PFS \u2013 potential paradigm shift<\/td><\/tr><tr><td><strong>Competitive Pipeline<\/strong><\/td><td>Amivantamab (Rybrevant, J&amp;J) \u2013 IV bispecific approved post\u2011chemo; mobocertinib (Takeda) \u2013 withdrawn due to toxicity<\/td><td>ZEGFROVY oral convenience + wild\u2011type selectivity safety advantage vs. IV competitors<\/td><\/tr><tr><td><strong>Mechanism Differentiation<\/strong><\/td><td>Irreversible EGFR inhibition with exon20ins specificity + wild\u2011type sparing<\/td><td>Reduced rash\/diarrhea vs. first\u2011generation EGFR inhibitors; improved tolerability supports first\u2011line use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR exon20ins Market Dynamics:<\/strong> First\u2011line EGFR exon20ins represents <strong>US$800 million\u20111.2 billion<\/strong> annual opportunity globally; current chemotherapy standard yields <strong>PFS ~6\u20117 months<\/strong> with significant toxicity; ZEGFROVY&#8217;s PFS superiority (magnitude to be disclosed at medical congress) supports premium pricing and rapid adoption.<\/li>\n\n\n\n<li><strong>Dizal Commercial Trajectory:<\/strong> First\u2011line approval would transform ZEGFROVY from <strong>niche post\u2011chemo therapy<\/strong> to <strong>frontline standard<\/strong>; US peak sales potential <strong>US$400\u2011600 million annually<\/strong> (2028\u20112030) assuming 40\u201150% first\u2011line market share; China market comparable size with faster volume ramp given domestic development origin.<\/li>\n\n\n\n<li><strong>WU\u2011KONG28 Regulatory Catalyst:<\/strong> Positive Phase 3 results support <strong>sNDA submissions<\/strong> US (FDA) and China (NMPA) <strong>H2 2026<\/strong>; potential approvals <strong>Q2\u2011Q3 2027<\/strong>; priority review designation likely given unmet need and chemo\u2011free differentiation.<\/li>\n\n\n\n<li><strong>Competitive Response:<\/strong> J&amp;J&#8217;s amivantamab pursuing first\u2011line approval (MARIPOSA\u20112 study); ZEGFROVY&#8217;s <strong>oral convenience<\/strong> and <strong>chemo\u2011free profile<\/strong> may drive physician\/patient preference vs. IV bispecific requiring hospital administration; combination studies (ZEGFROVY + chemotherapy or immunotherapy) may follow to address resistance mechanisms.<\/li>\n\n\n\n<li><strong>Dizal Pipeline Validation:<\/strong> ZEGFROVY success validates Dizal&#8217;s <strong>independent drug discovery capabilities<\/strong> (vs. in\u2011licensing dependency); irreversible EGFR platform supports follow\u2011on candidates for other EGFR\u2011resistant mutations (C797S, G724S); WU\u2011KONG28 multinational execution demonstrates global clinical trial sophistication for China\u2011origin biotech.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submission timelines, commercialization expectations, and competitive positioning for ZEGFROVY in first\u2011line EGFR exon20ins NSCLC. Actual results may differ due to risks including regulatory review outcomes, competitive dynamics with amivantamab, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60548,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,191,981,33],"class_list":["post-60547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-dizal-pharmaceutical","tag-sha-688192","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60547\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60547\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy\",\"datePublished\":\"2026-03-23T07:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547\"},\"wordCount\":631,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2301.webp\",\"keywords\":[\"Clinical trial results\",\"Dizal Pharmaceutical\",\"SHA: 688192\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60547#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60547\",\"name\":\"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2301.webp\",\"datePublished\":\"2026-03-23T07:00:03+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60547\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60547#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60547","og_locale":"en_US","og_type":"article","og_title":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.","og_url":"https:\/\/flcube.com\/?p=60547","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:00:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60547#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60547"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy","datePublished":"2026-03-23T07:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60547"},"wordCount":631,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60547#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","keywords":["Clinical trial results","Dizal Pharmaceutical","SHA: 688192","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60547#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60547","url":"https:\/\/flcube.com\/?p=60547","name":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60547#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60547#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","datePublished":"2026-03-23T07:00:03+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU\u2011KONG28 study evaluating ZEGFROVY (sunvozertinib) as first\u2011line monotherapy in non\u2011small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint, demonstrating significant PFS improvement vs. platinum\u2011based chemotherapy and positioning the irreversible EGFR inhibitor as the potential first and only chemo\u2011free, oral first\u2011line agent for this underserved mutation subtype.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60547#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60547"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60547#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","width":1080,"height":608,"caption":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60547#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Reports Positive WU\u2011KONG28 Results \u2013 ZEGFROVY First\u2011Line Win Positions as First Chemo\u2011Free EGFR exon20ins NSCLC Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60547"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60547\/revisions"}],"predecessor-version":[{"id":60549,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60547\/revisions\/60549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60548"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}